505 related articles for article (PubMed ID: 18052574)
1. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study.
Saddichha S; Manjunatha N; Ameen S; Akhtar S
J Clin Psychiatry; 2007 Nov; 68(11):1793-8. PubMed ID: 18052574
[TBL] [Abstract][Full Text] [Related]
2. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Saddichha S; Ameen S; Akhtar S
J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
[TBL] [Abstract][Full Text] [Related]
3. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
Perez-Iglesias R; Crespo-Facorro B; Amado JA; Garcia-Unzueta MT; Ramirez-Bonilla ML; Gonzalez-Blanch C; Martinez-Garcia O; Vazquez-Barquero JL
J Clin Psychiatry; 2007 Nov; 68(11):1733-40. PubMed ID: 18052567
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
5. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J
J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241
[TBL] [Abstract][Full Text] [Related]
6. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.
Volavka J; Czobor P; Cooper TB; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Lieberman JA
J Clin Psychiatry; 2004 Jan; 65(1):57-61. PubMed ID: 14744169
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
Basson BR; Kinon BJ; Taylor CC; Szymanski KA; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Apr; 62(4):231-8. PubMed ID: 11379836
[TBL] [Abstract][Full Text] [Related]
8. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.
Bobes J; Rejas J; Garcia-Garcia M; Rico-Villademoros F; García-Portilla MP; Fernández I; Hernández G;
Schizophr Res; 2003 Jul; 62(1-2):77-88. PubMed ID: 12765747
[TBL] [Abstract][Full Text] [Related]
9. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
10. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population.
Perez-Iglesias R; Crespo-Facorro B; Martinez-Garcia O; Ramirez-Bonilla ML; Alvarez-Jimenez M; Pelayo-Teran JM; Garcia-Unzueta MT; Amado JA; Vazquez-Barquero JL
Schizophr Res; 2008 Feb; 99(1-3):13-22. PubMed ID: 18053689
[TBL] [Abstract][Full Text] [Related]
11. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.
Bobes J; Garc A-Portilla MP; Rejas J; Hern Ndez G; Garcia-Garcia M; Rico-Villademoros F; Porras A
J Sex Marital Ther; 2003; 29(2):125-47. PubMed ID: 12623765
[TBL] [Abstract][Full Text] [Related]
12. Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics.
Chen JJ; Chan HY; Chen CH; Gau SS; Hwu HG
Pharmacopsychiatry; 2012 Mar; 45(2):64-71. PubMed ID: 22086749
[TBL] [Abstract][Full Text] [Related]
13. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.
Fraguas D; Merchán-Naranjo J; Laita P; Parellada M; Moreno D; Ruiz-Sancho A; Cifuentes A; Giráldez M; Arango C
J Clin Psychiatry; 2008 Jul; 69(7):1166-75. PubMed ID: 18588363
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
[TBL] [Abstract][Full Text] [Related]
15. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
Meyer JM; Pandina G; Bossie CA; Turkoz I; Greenspan A
Clin Ther; 2005 Dec; 27(12):1930-41. PubMed ID: 16507379
[TBL] [Abstract][Full Text] [Related]
16. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
17. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
[TBL] [Abstract][Full Text] [Related]
18. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
[TBL] [Abstract][Full Text] [Related]
19. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
[TBL] [Abstract][Full Text] [Related]
20. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]